mTR deficiency does not majorly impact iBIP phenotypes.
(A) Melanoma latency in BRAF-mutant mice with or without mTR deficiency.
(B) Progression-free survival on the BRAF inhibitor PLX4720 in iBIP mice with or without mTR deficiency.
(C) Number of non-synonymous mutations in BRAFi-resistant iBIP mice with or without mTR deficiency.
(D) Allelic fractions in the 10 mTR-null, BRAFi-resistant tumors.
(E) Summarization of results. Blue text indicates genomic status (mutation + SCNAs).